Pulse lineResearch With Heart Logo

Comparison of the prognostic value of left ventricular hypertrophy in African-American men versus women.

TitleComparison of the prognostic value of left ventricular hypertrophy in African-American men versus women.
Publication TypeJournal Article
Year of Publication2004
AuthorsNunez E, Arnett DK, Benjamin EJ, Oakes MJ, Liebson PR, Skelton TN
JournalAm J Cardiol
Volume94
Issue11
Pagination1383-90
Date Published2004 Dec 01
ISSN0002-9149
KeywordsAged, Black or African American, Cardiovascular Diseases, Cohort Studies, Female, Humans, Hypertrophy, Left Ventricular, Male, Middle Aged, Risk Factors, Sex Factors, Ultrasonography
Abstract

Echocardiographically determined left ventricular (LV) hypertrophy may be a stronger risk factor of cardiovascular disease (CVD) for women than for men, although it is unclear whether reported gender differences are real or attributable to confounding. We evaluated echocardiographic LV hypertrophy (defined as LV mass/height(2.7) >/=51 g/m(2.7)) collected from the African-American population of the Atherosclerosis Risk in Communities Study. Incident CVD events (57 in men, 62 in women) were determined during a median follow-up of 4.9 years (interquartile range 4.3 to 5.6) and included nonfatal myocardial infarction, cardiac death, coronary revascularization, and stroke. We conducted 2 analyses. First, we created matched samples of 340 men and 812 women who had LV hypertrophy based on propensity score and estimated the gender-specific incidence rate ratios and population-attributable risks. Second, we evaluated the complete cohort (604 men and 1,113 women) with Poisson's regression after adjusting for age, body mass index, hypertension, diabetes mellitus, ratio of total cholesterol to high-density lipoprotein cholesterol, current smoking, and education level. LV hypertrophy was significantly predictive of incident CVD, and the association shown by analyses of matched propensity scores was similar in men and women (incidence rate ratio 1.88 vs 1.92, p = 0.97 for men, population-attributable risk 0.22 vs 0.26, p

DOI10.1016/j.amjcard.2004.08.012
Alternate JournalAm J Cardiol
PubMed ID15566908
Grant ListN01 HC 55022 / HC / NHLBI NIH HHS / United States
N01 HC55015 / HC / NHLBI NIH HHS / United States
N01 HC55016 / HC / NHLBI NIH HHS / United States
N01 HC55018 / HC / NHLBI NIH HHS / United States
N01 HC55019 / HC / NHLBI NIH HHS / United States
N01 HC55020 / HC / NHLBI NIH HHS / United States
N01 HC55021 / HC / NHLBI NIH HHS / United States